Macrolane Surgery

Macrolane is a breast and body-contour filler marketed by Q-Med in the UK since early 2008. It has received attention as a less invasive alternative to surgical breast enlargement, offering an increase of one cup size through injections that only take between 30 and 90 minutes - heralding the term "30 minute boob job".
The treatment involves injecting stabilised hyaluronic acid into the breast, buttock or other areas, and then moulding to the desired shape.The benefits are that it requires only a local anaesthetic and will leave no scarring, although bruising, swelling and discomfort for a few days are expected. The effect however only lasts for 12 months, after which further injections are required. The procedure has also drawn criticism as its long term effects are relatively unknown. In 2009 the journalist Alice Hart-Davis described the problems that she experienced after having the procedure. The only medical trial was supported by the manufacturers, involving 1000 patients in Japan, and anybody taking the procedure will be entered into a European-wide research trial
Initially, treatment in the UK was reasonably expensive, costing about £3000 for the initial injections, followed by £1400 for repeat injections each year in order to maintain the effect.The cost of initial injections has dropped as the treatment grows in popularity

Macrolane non-invasive injectable breast and body shaping treatment


In past years, the latest option for non surgical, scarless breast augmentation is an injection known as the Macrolane filler. Less invasive than plastic surgery, Macrolane breast injection restores volume simply and more safely. Macrolane breast injectionMacrolane breast and body shaper gel contains stabilized hyaluronic acid. Hyaluronic acid is a natural component of our skin .
Macrolane

Macrolane injcetion- the first breast and body shaping treatment using hyaluronic acid. It is based on Q-Med's unique patented NASHA™ technology (Stabilized Non-Animal Hyaluronic Acid) which has been used in over 9 million treatments in over 70 coutries worldwide. Use of NASHA has been clinically proven and well documented in facial aesthetics for over 10 years.


Photo: Example of Macrolane treatment
Macrolane Macrolane breast enchancer is injected deep into the subcutis under local anaesthetic. Macrolane VRF filler comes in two formulations that can be injected seperately or in combination to ensure full correction and smoothness of the skin surface. The formulation and volume of Macrolane filler used (either VRF 20 or VRF 30) will be dependant on the individual and treatment area. Dr Rodigo will advise you at your consultation the most appropriate treatment procedure.

Women who are considering breast augmentation with Macrolane breast filler will want to be reassured that the implant will not adversely affect the efficiency of future mammograms and/or the breast tissue itself. In one study, mammography after Macrolane breast filler injection for breast augmentation was evaluated. It was concluded that mammograms from these patients were easy to evaluate. Furthermore, routine supplementation of mammography with MRI does not appear necessary in patients treated with Macrolane breast injection . For the breast enlargement with Macrolane to increase of 1 cup size you need volume of 100ml in each side. The procedure is performed under local anaesthetic and takes about 30 minutes.It lasts about 1 year and can be repeated as and when desired.It can be used in all parts of the body. in women and men including for penile enhancement.
Anesthesia
The operation performed under a general anesthesia.

Inpatient

This is a major inpatient procedure.

Duration of operation

Breast asymmetry correction usually takes 2 to 2.5 hours, depending upon the extent of the work needed.

Time of Recovery
Usually within 2 weeks. The patient is able to resume normal activity, except for lifting. Required minimum stay in Budapest 10 days.

Possible risks and complications

Breast asymmetry correction is a major invasive plastic surgery. When performed by a qualified plastic surgeon, one trained in body contouring, the results are normally very satisfactory. However, as with all surgical procedures, there are some risks associated with breast asymmetry correction . There are also specific complications associated with the procedure. These include: infection, nipple asymmetry and poor healing, which can result in heavy scarring. Infection can be treated with antibiotics and drainage. You can reduce your risks by closely following your surgeon's instructions both before and after plastic surgery. The specific risks and the suitability of this procedure for a given individual can only be determined at the time of consultation. All plastic and cosmetic surgical procedures have some degree of risk.

After care

After the plastic surgery you may be swollen and in pain, which can be controlled by medication. Depending upon the type of surgery performed, you may be remain hospitalized for up to 2 days. Your doctor will give you instructions in your post-operative care.If you feel any severe pain, call your surgeon immediately. Most of the swelling and bruising should disappear within two weeks or so.Your surgeon will let you know when you are ready for exercise. During your healing period avoid drinking alcohol, which can lead to fluid retention and delay recovery.

Results
Most patients are extremely happy with breast asymmetry correction. There is a certain amount of increased self esteem and self confidence which may result.The degree of improvement varies from patient to patient. 
  

What is the Macrolane procedure?

The procedure is quite simple. It involves you being given a local anaesthetic to numb the area to be treated‚ followed by the making of a small incision in that area. The doctor will use a thin tube or cannula to inject the Macrolane gel into the subcutaneous layer (inner layer) of the skin.
You may be prescribed antibiotics either before or after treatment to reduce the risk of an infection.

How much does Macrolane cost?

This depends on what part of the body is being treated and the amount of gel used.
As you can imagine‚ the greater the area and volume of gel used‚ the greater the cost. Prices can range from £1‚500 up to £3‚000.
Costs of Macrolane vary between clinics so you will need to obtain a few quotes before making a decision.
http://t0.gstatic.com/images?q=tbn:ANd9GcQDzBTyKK3rcENj1J1PCFob3_mlMMlo8kJ9Q9Ne4639CVSrstYwZwdata:image/jpg;base64,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data:image/jpg;base64,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://t2.gstatic.com/images?q=tbn:ANd9GcTzE5FOe3tvLRxmk48_066Y7fjeLEOTtGvJEwcZEhvoB5218RNChttp://t3.gstatic.com/images?q=tbn:ANd9GcQF0dqTQHYAydezKwOIWre8sR22TeTURlD-CkaNmaxo6FGZ8VRjgghttp://t2.gstatic.com/images?q=tbn:ANd9GcTfLC3DKdLYmw0JtKzPHkrpIUnukVxnzLVg-8eBxb8-kUGRloYPdata:image/jpg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5Ojf/2wBDAQoKCg0MDRoPDxo3JR8lNzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzf/wAARCACaAH8DASIAAhEBAxEB/8QAGwAAAwEBAQEBAAAAAAAAAAAAAwQFBgIBAAf/xAA3EAABBAEEAQEGBAMIAwAAAAABAAIDEQQFEiExQRMGIlFhcaFCgZGxFDJSBxUjMzRicsFjgsL/xAAZAQADAQEBAAAAAAAAAAAAAAAAAQQCAwX/xAAfEQEBAAIDAAMBAQAAAAAAAAAAAQIRAyExBBJBEzL/2gAMAwEAAhEDEQA/ALn8LGz8I/ILx0bfDQn3tHwQnNAXlPT2Qe3wW2FH1DSo5yXCM/or/wCLhFYAU5sbY/H0uOJ+7ad3XKqY8EfqNftG4cD5K6+KM9tCC9kTTywJ9jcKTQm2vYDx4SuotbNCxwFPjeDXyVX1GgGqSWWQ4tLQLB5PxS2PQ/SEsLQBYCUlwWXvqnDkFVGD023xRCUy30CByjZwhlsjMRaR4QcHHY6MEtFhdOY5556RYRsPHSNloyGAADj9EWOZ2PRB93yEBzwWgoE842nrhPG2XcLKSzS7DMJR7vfwTAPCz+l5BdA1wNlpLVbjf6jQW+Vbjlv1BlNXRyV9FLyPtCnn+BQWyFyhXjjtHjFC0FnPhMR/JAfP6S727u007ntBdwjZaKyNLTTQhFvRTTuUItrwltqBu5aOUpMLu08QKvtLzN5BQZRrQPC5e2kZ1WbQ38jjygyz37ezwksmSwaTs4Bb81KyXbLWsWculDQnExyi+pP+loMN3+A2ysx7PuOyf/kP2WmxAPRFqvDxDyel3SW5GiSrTZ4TER5UVq/R+LkJkWAlYuEcHhEpPXEmqQZD2PKITfkLkhBFiPgvDzVhFcOUKTjpLZwCWSgfkgeoXni+V7Oau0KB33TN6W2SCuHCjRTZZYXBZx1zSD2nzN7UnUWExvrsBXpYiQpeZHtBNcJy9ll3AvZo3jyu/qkr7LUYoIhbazuixiHCbX4nOd91ooHD0210rMEGfqeJK6XsE+6fY09dpJ0u3yvdGt7XTu7kcXfl4UNenI0kRsBGaUlHJTR0ExG7cLRGMoOvi1fMF9om2k3MAjsVSXnAATjwlZxZNJU4m5ROwlLYj+U1lD3SCUli8TV48IjSvGwuAN8HwiCKwPou8Ztt4TOwDxSZbIPiFHhTczH3AjhW5qAPKnZArrmkvBLtKx2hkbWf0ilVwiCwglS5HenKSej2msd7mHjyq+PLc2j5MdVJypNkTyfAKNgzBuNCAaG0fspurShsMn0P7LzS3vfBGD4aFLfHo77aSGXcRyVTgcCKUbFbQCq43zWSsUo+kbvpKxu8JphsLccq4eO0pPwE1I4NBspOWVhvkH81miJuV55SDTslBT2SQbU3IdtooajS6dNbBuTLyKUbTsg+l4KclyAGgWtFZ29yJPskJ5dvNr2aayaSE81DkpHrRTXc1mHpeTk7dzo220HyTQH7qX7He0E2rMyIstjPUhAcHMFBwPHI+KJrHp5WJNjykbZG0h+xGlx4ONPMXF0sj9u7qmjqlTw/WY3fqbn3uE9Ym3EReXupWsGLbG3b4AWWll9fWA2+Ixf5lajAfTQC6lwympIrxu6qwOI7HKpQP4UoEbbB5TUUleVzaqtE+02x4pSI5+OSitygFpzsQ/7Q/aKXRMKIYgb687i1rnCw0Ds/cLC6F7ZalHqMTc+b14JXhrgWgFtnsUtX7c6a/WsSMRkCaEksJ6N9g/osdovsxmf3hFJmsDIo3hxG7l1eFVx/z+nfqbk/pM+vH6ZO4lpI5UrOkAAFo8+VtbQ5JUTLyd8u1vjv6qeRRtpdKN4274rnIyfTdy7grzTA5mKxt8ntK6nGXMdRPCy1HMuaOgUlPmccFSJcl8Ty112EnNmF3AK6Y4s5ZaOZWSXO2jkk0FptNh/h8KKI3uqz9SoOh6a98gy8ttAcsYez8ytK0+fPxXfHHUR8mW6/ONOk36hNITe55/RbLCFsFjhYfRxc1DtbfT2vDACSQuXPNVZwXeJxxc0cXS5jzCw7Xn6WmPRcR0f0QZsW29Kd2ozcwEcH7r12aGjhSJoHxctPCXOU5nDiQtyMWrMuZvHfCVlyQObpS357f6ku7JklNRMc4lbmLFuzmVmX5XWi4b8zIEjwfSaf1K+0/R5sl4fk8NP4VrsHDbFGGsbTR4CLlroSPWwhoCBkxWDYT0jSEvNRbyuO2tspqmI15NCvooJwnMlsmwtlmxg8qPPGGu6XbDLTlnNq+L72PG74tCdhjMg64U3TH3iM+VhVsR3Lh9lRO0l9fmOmROYDOB7rXAH81tNNka5g+Kk4OCG4IgI9545+qa0mT3Q1494Gj9Vy+RP1X8fL8aWGRpA8I5a17fFpCCvBTcfzUzvS8+GHk/D5JR+jRSOsi1Y2DwumtofNa2zUZmg47Tfpg/UJ6DS4o62sAr5J9vPYRowOOUbpBQYgamqDRwKXu6hQXDiSCkApUpLyLtNPpLSgVQRAnZQvgKTlNtWMjiwpGYfIWsfSy8daO4mB4PiUhWcR1vIuvmoekkBs7f8Ayk/qFZxjTlXPEOXqTGyz1XNJOVph1AlnDXjcB9iqjYxV8pPVWbDA9o53VfyRyzeLpw5azUcSXcAno32e1LxbLWuHlUI/moavOxyXwUdtVaSajMeW+U4zYaAC7bSX9UfFcmauikWjpeAPCE+ShYSwnLjRC9PPSY0+e8npCeV0eEKUj4pkVyTyVGzXVYVSd6iZ8ndFORnLwTSnAic/Mfsq8bqo2omjHcJz/vH7KuH8BVzxHl67H0U7VX8wRjsncVRZ/wDKm6h/qv8A0H7lPk/zWuHvM3hEUARQP2VBrOiPCm4/TVRiUFegI11dr0vXJ7C+cgnhkK+a8l3KG7sLtiYMsodlEL+EAeF07pMn0kiTmfYtGf2UrP0EEUyXkg89KLln3u1VyP5SpGV/2t4+ueXg/s8/fFOfO9WmGis97L/5WT/zWgZ/MFXr8R31/9k=http://t3.gstatic.com/images?q=tbn:ANd9GcQi4ke1mgIugNWUtxYC28m3pvzhtcTXsD-HBxosZ3yKi5qxkd88uAhttp://t1.gstatic.com/images?q=tbn:ANd9GcQQYtVGN5Yzew1OC-Cf8-I6RyGZ75dYJBd4WfXPJCyLGUJhTZKOXvfNR3hOhttp://t3.gstatic.com/images?q=tbn:ANd9GcQdMAGrVDsIaLKEOX48rKi2JJahIZZlE7nZQCpoV7AZSGt46_t28ghttp://t1.gstatic.com/images?q=tbn:ANd9GcT5BtetcIz5kVn0I3gN_Ql0UAhBNCKN8r2Jyft-aSqMFNdXhZJxhttp://t1.gstatic.com/images?q=tbn:ANd9GcRiqKg0CIOUuyFhvf5l-kvqoHx-qKCkwhewh4RK30Rc44pytlQuNQhttp://t0.gstatic.com/images?q=tbn:ANd9GcT0m04nI8ihn_FMJ56YY_N2gzCjJSHy_n6PkGFsc0c_fAo7cTN_AQhttp://t3.gstatic.com/images?q=tbn:ANd9GcSMVroCZ1mW8JQl2xkrnZEA8JAB9WE5tuYeK3zHEdAywsvU_vp6N5Yq3tSaBAhttp://t1.gstatic.com/images?q=tbn:ANd9GcSrqsCy50d2QE6yvoL9LPGtO_nIBOaCCdL2Sl0wMvG8PmQO0j0Mhttp://t1.gstatic.com/images?q=tbn:ANd9GcRiqKg0CIOUuyFhvf5l-kvqoHx-qKCkwhewh4RK30Rc44pytlQuNQhttp://t1.gstatic.com/images?q=tbn:ANd9GcSs-Ut6p_2OgoQUZjaLo2nXXuzYsWXTa75Mis3A9YSvEzhecDSkDBC2zOPEhttp://t1.gstatic.com/images?q=tbn:ANd9GcQsH1hzaPX1_GpQEBHaKgWDvlals5n1urOuORpqFIOzyrdYSa1cBTgETrtVhttp://t1.gstatic.com/images?q=tbn:ANd9GcTiI304thn54xHhG9P4kYXcSsubnQ_cZVOm4YkQdOLqr-A00VbQwAhttp://t2.gstatic.com/images?q=tbn:ANd9GcT0LzruYhWViBF2U-QJWAjca9Lc5QHJa1fP676TLsABxOzscxEX0Ahttp://t1.gstatic.com/images?q=tbn:ANd9GcQULMGmxBDB2yKhCSv4wCWwDUyMCHyq61gJKnLDfYmoXslbtCPDWwhttp://t0.gstatic.com/images?q=tbn:ANd9GcR7TjGag5OmINrnKUBOvtxI17v9S0O_-o3-5RCjQLKGwHwfq7k1gghttp://t1.gstatic.com/images?q=tbn:ANd9GcQvzmsYU73hf6jW-H1W2Is5LV92XsS_d-fE2ZDbq_or4GeWIidLYAHLrK_Yhttp://t3.gstatic.com/images?q=tbn:ANd9GcQF8OJ682rY5urfgZx8mIyn13s9FgpXqyHsG79HLWFoFIIyFbhqwghttp://t0.gstatic.com/images?q=tbn:ANd9GcTmAbdqmX_Cf9YcF2rlg18DnD7ZYrJt_9zoXrchoAJpt3z0wqO0KA

0 comments: